DDInter844 DDInter1376
An alpha-2 selective adrenergic agonist used as an antihypertensive agent. [PubChem]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Guanabenz {u} (Compound) resembles {v} (Compound) Guanfacine
Guanabenz {u} (Compound) treats {v} (Disease) hypertension
Guanabenz {u} (Compound) binds {v} (Gene) ADRA2C
Guanabenz {u} (Compound) upregulates {v} (Gene) CASP10
Guanabenz {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic alpha2-Agonists
Guanabenz {u} (Compound) downregulates {v} (Gene) CCNB2
Guanabenz {u} (Compound) causes {v} (Side Effect) Bronchospasm
Guanabenz {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Guanabenz {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Guanabenz (Compound) resembles Guanfacine (Compound)
Guanabenz (Compound) treats hypertension (Disease)
Guanabenz (Compound) binds ADRA2C (Gene)
Guanabenz (Compound) upregulates CASP10 (Gene)
Guanabenz (Compound) is included by Adrenergic alpha2-Agonists (Pharmacologic Class)
Guanabenz (Compound) downregulates CCNB2 (Gene)
Guanabenz (Compound) causes Bronchospasm (Side Effect)
Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin